Enanta culls internal NASH work, betting on an out-licensing strategy in the disaster-strewn field
Cracking NASH has been the holy grail for years in liver drug development, but the field has so far proven a wasteland for biotech. One biotech is now offloading in-house clinical work for two of its NASH drugs after one posted lackluster results as a solo therapy.
Enanta Pharmaceuticals has halted internal development of its two FXR agonist NASH drugs, EDP-305 and follow-up candidate EDP-297, and will pivot to an out-licensing strategy after early data turned up little chance of success for either drug as a solo agent, the company said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.